NCT00271570

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.

Detailed description

This study is an exploratory, pilot study to examine tolerance and pharmacokinetics of infliximab in infants and children with acute Kawasaki Disease.

Conditions

• Kawasaki Disease

Interventions

Type	Name	Description
DRUG	Infliximab (Remicade)	Remicade was 5 mg/kg IV (single dose)
BIOLOGICAL	Intravenous immunoglobulin (IVIG)	2nd dose of IVIG (2g/kg)

Timeline

• Start date: 2004-04-01
• Primary completion: 2006-10-01
• Completion: 2006-10-01
• First posted: 2006-01-02
• Last updated: 2010-06-14
• Results posted: 2009-12-29

Locations

1 site across 1 country: United States